

24 March 2026

ASX Announcement

Appointment of Dr Charmaine Gittleson as a Non-Executive Director

PolyNovo Limited (ASX: PNV) is pleased to announce the appointment of **Dr Charmaine Gittleson** as a Non-Executive Director, effective 1 April 2026.

Dr Gittleson brings extensive global experience across healthcare, life sciences and governance, with a background spanning clinical practice and research, medical leadership, regulatory strategy, product development and board oversight. She is the former Chief Medical Officer of CSL Limited, where she held senior global leadership roles across clinical research and development, regulatory engagement and patient safety, including extended tenure in the United States.

Dr Gittleson is currently Chair of Percheron Therapeutics Ltd (ASX: PER) and a Non-Executive Director of George Medicines Ltd, and has previously served as Chair of Patrys Ltd (ASX: PAB). She has deep experience working with regulated healthcare products, global markets and complex stakeholder environments, and is a Graduate of the Australian Institute of Company Directors.

PolyNovo Chair Leon Hoare said:


"We are delighted to welcome Charmaine to the PolyNovo Board. Her depth of experience in global healthcare, regulatory strategy and patient-focused innovation will be highly valuable as PolyNovo continues to scale internationally. Charmaine brings strong clinical insight, governance discipline and a proven record of leadership in complex, regulated environments, and we look forward to her contribution."

The Board considers Dr Gittleson to be an independent director for the purposes of the ASX Corporate Governance Principles and Recommendations. An Appendix 3X will be lodged separately.

This announcement has been authorised for release by PNV's Company Secretary, Amy Demediuk.

Further information:

Amy Demediuk, General Counsel & Company Secretary
Mobile: + 61 419 858 691
Email: amy.d@polynovo.com



About PolyNovo®

PolyNovo (ASX: PNV) is a leading medical technology company transforming the management of complex wounds. Headquartered in Melbourne, Australia, it has international operations in the United States, United Kingdom, India, Hong Kong and Singapore and several other markets supported by distributor partners.

The proprietary NovoSorb® polymer is addressing significant unmet needs in wound care, as evidenced by its clinical adoption and patient outcomes, and the Company is leveraging the technology platform to develop new products and markets.

Achievements to date, including continued revenue growth, profitability, numerous clearances and registrations, as well as market leadership in several geographies, provide a strong foundation for continued growth.

For more information see polynovo.com

About NovoSorb® Technology

NovoSorb® is a proprietary biodegradable polymer platform designed to support tissue regeneration in complex wound care. The unique characteristics of NovoSorb® provide several key advantages including excellent biocompatibility, control over physical properties, a programmable bio-resorption profile and can be produced in many formats including film, fibre, foam, and coatings.

NovoSorb® BTM is a synthetic dermal scaffold for the regeneration of the dermis when lost through extensive surgery, trauma or burn. This innovative product was the first to be commercially available utilising NovoSorb® technology and is supported by a growing body of independent clinical evidence.

NovoSorb® MTX is PolyNovo's latest advanced wound care product; a fully synthetic dermal matrix, developed in response to surgeon demand for a dermal substitute without a temporising, sealing membrane. Since receiving FDA 510(k) clearance in 2022, NovoSorb® MTX has rapidly gained surgeon adoption and is emerging as a key driver of growth.